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Abstract 
Public authorities have recently supported development of the biotechnology sector by 
encouraging start-ups and creating favourable environments such as incubators, a 
specialised stock exchange or technopoles. The different programmes to encourage biotech 
development (subsidies for research performed jointly by firms and academic labs, subsidies 
for start-ups, creation of incubators) seem to be successful if the results are estimated in 
terms of the number of new firms (around 300 SMEs still in existence, since 1990). On 1 
January 1999 France had just over 400 biotechnology SMEs employing a total of 15,000 
people, with an estimated turnover of 2 billion euros. Average size in terms of number of 
employees per firm is about 40, compared to about 140 in the USA. All in all, biotechnology 
remains a small emergent sector compared to others such as agri-food (over 4,200 French 
firms with 372,300 employees and a turnover of 100 billion euros) or pharmaceuticals 
(94,500 employees in 271 firms and a turnover of 28,5 billion euros). 
The creation of start-ups during the past ten years raises questions on the future of 
these new biotech firms (DBFs) in France and in Europe. Will consolidation occur in Europe 
and, if so, when? Will maturity of the biotech sector be accompanied by the progressive 
disappearance of many of these firms and the growth of a few of them? Will the sector be 
structured along the same lines as the automobile industry, with large firms with a high 
capacity for integration of research performed elsewhere and a large number of specialised 
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firms? What will the future be of the hundreds of small firms which focus on the local or 
regional market, especially service oriented firms?  
To answer these questions, this paper presents three business models of biotech firms. 
By referring to the governance modes of each business model of biotech SMEs, it provides us 
with a better understanding of the logic of development of biotechnology SMEs in France. 
The first part presents the linkages between business models and governance modes. The 
second part, based on a survey on half of the 400 dedicated biotech firms (DBFs) in France, 
presents an overview of these firms and their development. The third part presents an attempt 
to map out the development trajectories of SMEs and the respective leading forces in each 
type of firm. Concluding remarks present three possible scenarios of the evolution of the 
sector. 
1. Introduction 
Public authorities have recently supported development of the biotechnology sector by 
encouraging start-ups and creating favourable environments such as incubators, a 
specialised stock exchange or technopoles. The different programmes to encourage biotech 
development (P. Monsan, 1999) (subsidies for research performed jointly by firms and 
academic labs, subsidies for start-ups, creation of incubators) seem to be successful if the 
results are estimated in terms of the number of new firms (around 300 SMEs still in 
existence, since 19901). On 1 January 1999 France had just over 400 biotechnology SMEs 
employing a total of 15,000 people, with an estimated turnover of 2 billion euros2. 
Estimates based on the survey initiated by the MENRT* are consistent with information 
published by Ernst and Young, although they indicate a higher number of firms in France. 
Average size in terms of number of employees per firm is nevertheless similar: about 40 
persons, compared to about 140 in USA. All in all, biotechnology remains a small 
emergent sector compared to others such as agri-food (over 4,200 French firms with 
372,300 employees and a turnover of 100 billion euros) or pharmaceuticals (94,500 
employees in 271 firms and a turnover of 28,5 billion euros3). 
                                                     
1 As the mortality rate is high, our figure under-estimates the number of firms set up during the last 10 years. 
But it gives an idea of the number of firms set up and which survive. 
2 This figure does not take into account divisions in certain firms specialised in biotechnology, with over 500 
employees. 
* Ministère de l'Education Nationale, de la Recherche et de la Technologie. The French ministry in charge of 
research. 
3 Sessi, 1999: "La situation de l'industrie", Annual Business Survey, Sessi, Paris. 
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The creation of many start-ups during the past ten years raises questions on the future of 
biotech SMEs in France and in Europe. How will consolidation of the sector occur? Will 
maturity of the sector be accompanied by progressive disappearance of SMEs and the 
growth of firms? Will it be structured like the automobile industry, around collaboration 
between firms with a high capacity for integration of research performed elsewhere, and 
specialized firms such as parts manufacturers? What will the future be of the hundreds of 
small firms which focus on the local market or a specific technology, and which have 
grown at a moderate pace over the past ten years? 
To answer these questions we have chosen to reason in terms of business models, that is, 
organisational models covering the targeted market (final or intermediate market), 
networks of partners, and shareholders. A business model corresponds to a set of key 
resources for the firm's development and to a mode of securing these resources within the 
organisation. It provides insight into the development logic of biotechnology SMEs in 
France. 
The aim of this paper, based on the results of a 1999 survey on all biotech SMEs in France 
is to understand the development logics of these firms. The first part defines the concept of 
a business model. The second part is an overview of biotech firms in France and their 
development, based of the survey carried out in 1999. It presents three business models for 
biotech SMEs. The third part is an attempt to map out the development trajectories of 
SMEs and the respective leading forces in each type of firm. Concluding remarks present 
three possible scenarios for the evolution of the sector. 
ORGANISATION OF FIRMS AND BUSINESS MODELS 
Business model as an Archetype 
The formal and informal structures of firms and their external linkages have an important 
bearing on the firm's growth rate. According to Teece (D. J. Teece, 1996), firms' distinctive 
modes of governance depend primarily on their boundaries, formal internal structure, 
informal structure and external relations. Rather than specifying all possible combinations, 
we have chosen to reason in terms of archetypes. 
Greenwood and Hinings (R. Greenwood and C. R. Hinings, 1993) define an archetype by 
two general statements: “First, organizational structures and management are best 
understood by analysis of overall patterns rather than by analysis of narrowly drawn sets of 
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organizational properties. [….] Second, patterns are a function of the ideas, beliefs, and 
values – the components of an interpretive scheme – that underpin and are embodied in 
organizational structures and systems”, (p 1052).  
Research on archetypes generally focuses on large firms; only one of the archetypes 
identified by Teece (1996) describes a small organisation (the individual inventor and the 
stand-alone laboratory). Greeenwood and Hinings contrast bureaucratic organisations and 
professional organisations. These typologies are multidimensional. Generally, they are 
based on organisational structures (rule-making, formal structures of authority, etc.) or on 
decision-making processes. Yet a range of writings reflects this view of archetype as 
configured structures expressing underlying values. Ranson, Hinings and Greenwood (S. 
Ranson, C. R. Hinings and R. Greenwood, 1980) emphasise that it is necessary to 
investigate the social mechanisms which determine the structuring process and shape the 
ensuing structural forms if we are to fully understand the formation of organisational 
structures. One of the dimensions that has been identified to study architectural practices is 
motives for work, i.e. an intellectual ethos, a set of ideas about the architecture, that results 
in a particular set of organisational arrangements. A similar idea has been developed in 
Karpik’s conception of a 'logic of action' and in Callon and Vignolle’s notion of 'forms of 
coherence' (M. Callon and J. Vignolle, 1976).  
High-tech SMEs are created around a sound project supported by the creators. This project 
strongly structures the resources and competencies that the firms will have to mobilise.  
Mobilising resources to innovate 
While research on strategy has traditionally focused on an analysis of competition (M. 
Porter, 1980), analysis in terms of resources and competencies has been developing since the 
mid-1980s. This change reflects the shift of interest from external towards internal analysis: 
organisations are studied from within rather than in relation to their environment. The 
increasing openness of organisations has gone hand in hand with a relative disappearance of 
boundaries. Thus, the theory of resources, for which the definition of boundaries is less 
fundamental than it is for approaches focused on competition, seems particularly rich. It 
proposes an analysis of the organisation and of its competitive advantages in terms of 
tangible and intangible resources and competencies (J. B. Barney, 1991; J. B. Barney, J. C. 
Spender and T. Reve, 1994; R. Grant, 1991; G. Hamel, 1991). Competitive advantage is 
based on a logic of comparative advantages derived from resources and competencies. It is 
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by knowing and controlling them that strategic options can be defined and a competitive 
advantage created. 
Resource-based theory (E. Penrose, 1959; M. Peteraf, 1993; J. L. Arrègle, 1996; J. Mahoney 
and J. Rajendran Pandrian, 1992; P. Shrivastava, A. S. Huff and J. E. Dutton, 1994; M. V. 
Russo and P. A. Fouts, 1997) like the theory of dependent resources (J. Pfeffer and G. R. 
Salancik, 1978; P. S. Tolbert, 1985; A. Valette, 1994; K. Weick, 1979) distinguishes 
resources which are inputs into the production process and can be of various kinds (capital, 
human resources, equipment, cooperative networks, or commercialisation networks, 
reputation or scientific visibility), on the one hand, and competencies which are related to 
the use and implementation of those resources, on the other. The sustainable nature of 
competitive advantage depends on the difficulty another organisation would have imitating 
the source of the reference organisation's success. 
This approach seems particularly fertile for analysing an industry that relies primarily on a 
combination of resources because few of its products have as yet been marketed. Studies in 
organisation theory are based on a logic of supply. The identification of critical resources 
for each organisation helps to understand logics of cooperation and to contribute towards 
the analysis of modes of inter-organisation coordination in the context of resource-based 
theory. 
In the biotechnology sector, several authors have analysed firms' strategies for acquiring 
and stabilising the resources needed for their business and growth. G and A Eliasson (G. 
Eliasson, Eliasson, A., 1996) point out the differences of the biotechnology sector 
compared to other industrial sectors:  
(1) Biotechnology is a sector that stems from academic research. Technically, the 
differences between an academic and a private laboratory are small. However, 
competencies involved in implementation and industrialisation differ substantially.  
(2) The main costs are those of research and commercialisation; production costs are 
relatively low. 
(3) As Henderson et al. (R. Henderson, L. Orsenigo and G. Pisano, 1999) point out, 
discoveries result from the combination of different corpuses of knowledge and know-
how. G. and A. Eliasson define all the competencies necessary for the discovery of 
new products or processes as a "competence bloc". 
(4) Finally, when the competencies needed to innovate are scattered among several 
organisations, agreements between public and private organisations become essential. 
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G. and A. Eliasson show that the notion of a competence bloc exceeds purely scientific 
competencies: "to have a business potential, a competence bloc requires a minimum of 
more or less related competencies embodied in active, competent and resourceful 
consumers, innovators who select innovations that satisfy economic criteria, competent 
venture capitalists who recognize and finance commercially viable opportunities, and 
industrialists". These elements are added to the ability to form partnerships with 
laboratories or firms with complementary resources. 
To understand the logics underpinning the creation and development of biotechnology 
firms in France, the firms in our sample can be positioned in relation to the different 
dimensions defined by G. and A. Eliasson : 
- Following the article by A. Nilsson (A. Nilsson, 2000), two models of firms are 
identified. In the first, firms have integrated all functions, including commercialisation 
and marketing. These firms cater for final consumers, to whom they supply agri-food, 
cosmetic or pharmaceutical products. In the second model, biotech firms supply 
intermediary products which are integrated into the production processes of firms 
directly in contact with consumers. In our study, consumers' competencies were 
identified in this way. 
- Industrialists and venture capitalists have a similar role. They help to finance firms by 
providing capital. They also link the firm, initially based on a scientific idea, to the 
business world. This connection has several forms: contact with potential industrial or 
commercial partners; opening of a market, particularly that of the parent company or 
other firms in the group, advice and support in strategic management (see Nature 
Biotechnol N°17, Supplement on Bioentrepreneurship, May 1999). 
- Liebeskind et al. (J. P. Liebeskind et al., 1996) describe the environment of 
biotechnology SMEs as hyper-competitive. In this context, the appropriability of 
research results in central. Innovation opportunities are grabbed particularly fast (D. 
Teece, 1986) when the appropriation regime is strong. International patent laws 
stipulate that only the first to discover a product or process can take advantage of the 
discovery (if it is patented). Thus, biotech SMEs compete with established firms which 
finance their own research – as Arora and Gambardella (A. Arora and A. Gambardella, 
1990) show –, with other organisations engaged in biotech research (SMEs and 
universities) and with potential entrants.  
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Zucker et al. (L. Zucker, M. R. Darby and J. Armstrong, 1994) show that 97% of star 
scientists work in universities or non-profit research institutes. Only 3% work in 
enterprise.  
- Even though star scientists do not work directly in biotech firms, these firms do have 
strong links with the academic world. Dedicated Biotech Firms (DBFs) are thus forced 
to develop organisational arrangements that give them access to external intellectual 
resources. The essential character of external resources is threefold:  
(1) Relations with the academic world enables firms to explore a wide variety of 
hypotheses while maintaining a large degree of flexibility. Thus, exploration of 
scientific hypotheses in other organisations enables them to reduce costs and to avoid 
sunk costs, but still to be the first to benefit from the discovery.  
(2) Powell (W. W. Powell, 1990) argues that social networks are the most efficient 
organisational arrangement for sourcing information because information is difficult to 
price (in a market) and to communicate through a hierarchical structure. Social 
networks serve as sources of reliable information, which is essential to efficient 
organisational learning. When knowledge is distributed among several organisations, 
not only access to information but also learning how to work in partnership become 
key variables in competition (W. W. Powell, Koput, K.W., Smith-Doerr, L., 1996; B. 
L. Simonin, 1997).  
(3) Relations with the academic world, via the social networks in which the creators of 
the firm are involved, enable the firm to have access to unique scientific expertise that 
is a critical resource for its survival and development. 
 
To sum up, the hypothesis tested in this article is that French biotech SMEs can be 
described in terms of a limited number of business models structured by the way in which 
these DBFs mobilise competencies in order to innovate. 
DATA AND METHODS 
Biotechnology: a small industrial sector 
The French biotechnology sector is an emergent sector consisting of about 400 small 
businesses in widely diverse markets. 221 firms responded to our survey conducted in the 
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first half of 1999. 186 complete answers were processed. (See box for the detailed 
methodology of the survey.) 
Firms that do customised work for companies in direct contact with consumers 
Like everywhere else, French DBFs have little contact with the end user. Only 12% of 
firms have such contact (mainly for agri-food products, cosmetics and, to a lesser degree, 
human health). 88% of biotech firms are active suppliers of intermediary goods and 
services for other firms in the fields of human or animal health, cosmetics, environment or 
agri-food. 
As shown in Table 1, the majority of biotech SMEs specialise in the design, development 
and production of customised genetic or biological material. A small minority (20%) is 
engaged in product development (human health – 8% and other, apart from drugs – 12%). 
Most firms are service providers. They sell biological material to companies in all sectors, 
enabling them to produce either more quickly or better quality products (e.g. more 
standardised and better controlled quality), at a lower cost. 48% of firms produce goods, 
18% supply products and services and 34% provide services only. 
 
Insert table 1 here 
 
The activity of biotechnology firms is described in relation to two dimensions: the business 
sector in which the firm sells its products or services, and the company's core competencies 
(or speciality). The sectors in which it sells its products or services are described in the 
following way: 
- The firm caters for a sector: agriculture or the agri-food industries (26%), cosmetics 
(4%) or pharmaceuticals (37%). 
- The firm commercialises its products and services in two sectors which do not require a 
marketing license: agriculture/agri-food and cosmetics (1%). 
- The firm generates a cash flow from the sale of products and services in the cosmetic 
or agri-food sector and carries out research in the human health sector – a sector in 
which it takes longer to generate turnover (12%). 
- The firm has generic know-how which it uses in all sectors (equipment, materials, etc.) 
(21%). 
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The core competencies of the firm describes the products and services that it designs, 
produces and markets. Four categories have been identified: 
- Product development (20%). The firm's business is production and marketing of 
products. It does not produce customised products only; it also mass produces. 
- Diagnosis and creation of tests and/or biological material (55%). These firms develop 
two complementary activities: a) as service providers to other companies they create 
tests, biological material with specific characteristics, and customised diagnoses; and b) 
they design, produce and commercialise diagnostic kits, either directly or through other 
companies. 
- Design and production of equipment and material for laboratories. These firms cater 
for all sectors. They account for 9% of the total. 
- Development aid methods or sequencing. These firms design methods enabling firms 
to improve their processes or to market their products more effectively (e.g. CRO4). 
These firms, which account for 17% of the total, cater primarily for the pharmaceutical 
and agri-food sectors. 
 
To sum up, out of the firms active in the human health sector, few are directly engaged in 
the production of drugs. Firms in the agriculture, agri-food or environment fields produce 
mainly seeds or foods with specific characteristics (health or functional food). Service 
firms in these sectors mainly provide tests or diagnostic kits for agriculture or agri-food 
and the environment. SMEs focused on the cosmetic or animal health sectors have largely 
the same characteristics: close to firms in the human health field, they develop products or 
services which do not require specific marketing licenses. This market positioning often 
corresponds to a strategy for progressively conquering the human health market. 
Firms active in all the sectors are mainly those which design and develop generic tools or 
methods (such as sequencing or instrumentation). 
Mainly new DBFs 
Close to 70% of firms which were still alive in 1999 had been founded after 1990. Firms 
that are 20 years old or more now account for 12% of the sample, while the most recent 
firms account for 69% of the total. Less than 20% of all firms were created between 1980 
and 1990. 
                                                     
4 Consultancy research organisation 
10 
C:\Documents and Settings\vincent\Mesdocs\archives definitives\VM Articles publiés\Business models biotech statcan Livre 2000\Vm-
avr00.doc  07/02/06 
 
Insert table 2 here 
 
The average number of employees of an DBF is 37 persons, for an average turnover of 480 
KE*. Whether in terms of turnover or number of employees, these firms remain small. 72% 
have a turnover under 1.5 ME**, compared to only 4% with over 15 ME. 24% have a 
turnover between 1.5 and 15 ME. Moreover, 55% employ fewer than 10 persons and only 
14% employ over 50 persons. 31% employ between 10 and 50 persons. Although a slight 
difference is apparent between recruitment and generation of revenue, at the time of start 
up, the number of employees and the sale of products and services remain very closely 
linked. Firms established before 1980 and still alive in 1999 grew very fast, especially 
those active in the human health sector. Comparatively, the firms created between 1980 
and 1990 grew more slowly. 
Firms active in the agro-food or agronomic sectors and those which are active in the 
pharmaceutical sector are larger than the others in terms of number of employees. Business 
creation was spread out over time, and across all sectors equally. 
BUSINESS MODELS 
To understand the growth of firms and the dynamics in which they are engaged, we chose 
to reason in terms of business models. A business model describes a category of firm in 
relation to the market it targets, its expected growth and the organisation of its activity. The 
biotech firms which responded to our survey are spread out in the following way, in terms 
of criteria borrowed from Eliasson: 
 
Insert table 3 here 
 
The four dimensions proposed, following G. and A. Eliasson, enable us to define three 
business models structured around management of industrial property, networks of 
shareholders, and the firm's position in the market. 
Table 4 presents a matrix of correlation between the different indicators (shareholders, 
final or intermediary market, customer sector, patent, age of firm, turnover and number of 
employees). 
                                                     
* thousand euros 
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Insert table 4 here 
 
We can thus identify four groups of firm, the characteristics of which are given in Tables 5 
and 6: 
 
Insert tables 5 and 6 here 
 
Group A : Firms with good development potential 
These firms vary in size. Their main characteristics are that they patent and are financed by 
venture capital and shareholders who are natural persons. Considered as the flagship of the 
French biotech industry, the 30 firms in this group have experienced rapid growth. They 
specialise in customised production and service provision for pharmaceutical companies. 
They are rarely presented in sectors related to agriculture or agri-food. 28 out of 30 were 
created after 1980. Close to 50% of these firms employ over 10 people and a third have a 
turnover greater than 1.5 ME. 
Development of these firms was based mainly on the presence of national and international 
capital investors. Present from the start, venture capital companies played an active part in 
their orientation and put them on a fast-growth trajectory. The widening of the circle of 
shareholders beyond the family circle enabled these companies to benefit from advice, 
contacts, human capital and an introduction into networks they hardly knew or that would 
have taken time to discover (under 30% of the 186 firms have a venture capital company as 
a shareholder). Quotation on the stock exchange enabled venture capitalists subsequently 
to sell their shares and to withdraw – a condition sine qua non for the perpetuation of 
financing of biotech firms by venture capital. The presence of venture capital firms in these 
companies paved the way for a transition from an essentially domestic environment 
(family capital, network of new entrepreneurs) to a truly entrepreneurial environment. 
Fast growing firms rely on partnerships with French or foreign universities, as well as with 
public institutions such as the CNRS or INSERM, to maintain their scientific and 
technological competencies. For these firms, proximity to a pole of scientific excellence is 
essential if they are to benefit from spillovers from public research, through interpersonal 
                                                                                                                                                                 
** million euros 
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relations and international interaction of academic laboratories. To attract the best 
researchers, PhDs and post-docs – all potential partners – these firms have an interest in 
taking advantage of centres of academic excellence both at start up and during their 
development. Several authors (D. Audretsch and P. Stephan, 1996; M. Feldman, 1999; J. 
P. Liebeskind et al., 1996) have highlighted the role of proximity between high quality 
academic research and DBFs. Even if these firms are developing collaborative researches 
with academic labs wherever they are, these DBFs are located near the main pole of 
excellence, Paris and Strasbourg. Partnerships with other firms, especially pharmaceutical 
firms, enable them to transfer their technologies. Given the fact that these firms are 
essentially providers of goods or services to pharmaceutical companies, their turnover is 
dependent on formal collaboration, as shown by Sharp and Greis et al. (N. P. Greis, M. D. 
Dibner and A. S. Bean, 1994; W. W. Powell, 1998; M. Sharp, S. J. and I. Galimberti, 
1994). These contracts are one of the ways of getting round barriers to entry, on both a 
scientific and a commercial level. They also enable these firms to benefit from faster 
learning and to acquire additional competencies. 
Group B : Firms which develop in niches 
These firms all started with the idea of an entrepreneur who mobilised family capital (60% 
of the firms have only natural persons as shareholders). Very few of them have venture 
capital firms or other firms among their shareholders. They have little capital and generate 
turnover from the outset, especially through customised production or service provision. 
Their turnover is substantially lower (under 1.5 ME) than that of other types of firm. They 
rarely develop an activity which caters specifically for pharmaceutical companies. On the 
other hand, they have a strong presence in the agriculture and agri-food fields. They rarely 
patent their technology although they sell their products to final consumers. These firms 
look in their immediate environment – family and geographic – for catching the resources 
to survive and grow. Often they have very few links to networks of actors active in 
biotechnology (consulting firms, venture capital firms, academics or recognised 
researchers, ANVAR, ministries, etc.). Relations with the market and users of their 
products and services are formed on the basis of geographic proximity. They grow as they 
expand their clientele beyond the local market, by broadening the range of their services or 
specialising their supply so that they become the leader in their market. 
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Group C : Firms attached to a group 
The capital of firms in this group is mainly in the hands of natural persons and other firms. 
Venture capital is seldom present in firms in this group5. Either they were bought out when 
they were independent, or they were created directly by their parent company. In fact, one 
of the strategies of pharmaceutical or seed companies is to create biotech firms, either 
alone or in partnership with other firms. Biotechnologies are a high-risk business whose 
development relies on specific competencies that are sometimes difficult to maintain 
within a group. Small structures are more flexible and adjust better than large ones to 
changes induced by the production of new scientific knowledge. Finally, investing in a 
biotech subsidiary also enables firms to set up in countries where they can take advantage 
of externalities of its research and of new markets. Yet firms in this group form fewer ties 
with academic research than others, especially with INSERM and the CNRS. It seems that 
the parent company or shareholding company is a special partner, including for research. 
Thus, major French companies (Limagrain, Aventis, etc.) and foreign corporations 
(Monsanto, etc.) have invested in subsidiaries created ex nihilo and specialised in 
biotechnology, in order to set up in France (e.g. BioSepra, Bachem Biochimie or 
Diagnostica Stago) or to isolate their biotechnology activity from their core business (e.g. 
Syral, Biosem or Limagrain Genetics). These firms, which benefit from the captive market 
of the parent company and the networks and markets to which it affords access, see their 
turnover increase faster than that of independent firms. Companies in this category are 
much bigger (in terms of number of employees) and have a significantly higher turnover 
than those in the other categories. This growth is based above all on the parent company's 
internal network. On the other hand, the fact that they patent less may not be significant, 
for some patents may be registered by the parent company. 
Group R : New Biotech Firms (DBFs) 
This group comprises firms that had been in existence for less than two years at the time of 
the survey. They are thus constantly evolving. Significantly smaller (Table 6) than firms in 
the other groups, in terms of number of employees and turnover (often two or three 
                                                     
5 Since there is no significant difference in the set-up dates of the different groups, it seems likely that 
venture capital invests little in firms in this group, for its absence cannot be imputed to a withdrawal of 
venture capital companies after the sale of their shares. 
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persons, some of whom work part time), DBFs have registered few patents6. On the other 
hand, they have persuaded capital investors to become shareholders (Table 5). Capital 
investors are often firms in the seed business and are often regional and multi-sectoral. 
Their capital investments enable biotech firms to survive, for many of these DBFs generate 
no turnover. They are very seldom engaged in the production of goods for final consumers. 
By contrast, they have partnerships with research organisations, especially INSERM. The 
youngest firms are oriented essentially towards the pharmaceutical sector. They are less 
present in the agriculture, agri-food and cosmetic sectors. 
COMPETING BUSINESS MODELS 
Three logics for three business models 
The statistic analysis reveals four types of firm which were designed differently from the 
outset. Firms in Group A base their development on their capacity to produce and transfer 
their scientific results. For them, a critical resource is access to scientific competencies and 
techniques developed by academic research. Their development logic can be summarised 
as follows: 
Scientific discovery that can be transferred--> registration of patent --> 
entry of venture capital into shareholding to finance an R&D activity--
> strong ties with the academic world--> partnerships with 
pharmaceutical firms to gain access to the market and transfer 
research--> entry into the new market. 
For these firms, often created by researchers from large groups or by academic researchers, 
insertion in the scientific network is a condition for growth. It is not sufficient, however, 
for firms must not only develop high-tech research but also transfer and commercialise 
their results. This often involves research or development contracts with a big company, in 
which the SME undertakes to provide its partner with specific materials, technologies, 
know-how or expertise. Relations are formed on the basis of a specific competency 
recognised by the big firm. The SME's technological lead depends on the quality of its 
                                                     
6 In some cases it is difficult to identify patents since some were registered in the name of the inventor before 
being incorporated into the company's assets. 
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research, and the launching of the activity relies on capital input for the development of the 
product or process. 
Firms in Group B are based on a different logic. Created by researchers or engineers who 
have identified a commercial opportunity, they focus on specific niches and generate 
turnover very soon after creation. These firms are part of a local economic fabric resulting 
from contracts developed by the entrepreneur during his or her previous activity. 
The development logic can be outlined as follows: 
Identification of a niche or idea to transfer research --> creation of a 
firm based on family capital --> commercialisation of products or 
services to generate a cash flow --> development of business by 
expansion of the market. 
In this logic, the firm's key resources are its first customers and its regional or sectoral 
position which enable it to be known.  
Firms in Group C rely on the group to develop their business. They progressively expand 
their clientele.  
Competition or complementarity 
Competition between firms occurs when they are present in the same market. In that case, 
it is the firms' products or services that compete. Given the emergent character of the 
biotechnology sector and the innovative nature of the services or products offered, markets 
are constructed along with supply. Thus, it seems that, at this stage, firms are rivals in their 
market segment, within the same business model. The market, as usually described, 
represents a key resource in the development of firms only for those belonging to Group B. 
On the other hand, all firms are rivals for the acquisition and integration of key resources 
for development. 
Table 7 describes the different areas of competition. As they are based on research and 
most of them are financing their activities thanks to capital investments, firms on the 
different business models are not only competing on the markets. They are also competing 
to convince shareholders (and venture capitalists) to invest in their activities, to develop 
co-operation with established and promising academic teams (having a star scientist as a 
Nobel prize as a collaboration or in the scientific advisory board can boost your activity 
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and your share) and to contract with large firms to finance the development and the 
commercialisation of product.  
 
Insert table 7 here 
 
Resources needed by firms to grow are specific to each type of business model. Thus, 
firms compete within a business model. But competition between business models remains 
marginal, both in markets and for the acquisition of resources which, even if they are 
similar, are owned by different actors. 
CONCLUSION 
 
Still to be done 
ANNEXES 
Box: Characteristic of the survey 
At the initiative of the technology division (Biotechnology group) of the MENRT7, a survey 
was conducted on firms engaged in biotechnology research or development. A questionnaire 
was sent to 450 private organisations, irrespective of their size or status (listed or not). 221 
answers were received but they were largely incomplete. In order to obtain a representative 
sample, the data base thus obtained was matched with various other available data bases: the 
base created by the INRA/SERD team, The France Biotech base, the Genetic Engineering 
Directory, Infogreffe and Diane. Missing information was thus obtained and certain firms 
were added to the base when all necessary information was available. 
 
In order to standardise the answers, only organisations listed in the trade and commercial 
register as companies (SA, SARL, SNC) were selected. To guarantee the relevance of 
comparisons with information published by Ernst and Young (1999 Report), our analysis 
took into account only those firms with under 500 employees. Lastly, we excluded the rare 
biotechnology firms founded before 1960. The analysis was finally based on 186 enterprises 
on which full information was available. The sample analysed can be considered 
representative, essentially because over 60% of the firms listed in the France Biotech 1998 
directory and 90% of the firms in the Genetic Engineering Directory answered the 
questionnaire. By convention, we consider that the base analysed corresponds to roughly 
half of the biotechnology enterprises active in France. 
                                                     
7 A steering committee composed of Pascale Auroy (ARD), Christine Bagnaro (ANVAR), Patrice Blanchet 
(DTA/2, MENRT), Marie José Dudézert (DTA/2, MENRT), Anne Sophie Godon (Arthur Andersen) and 
Vincent Mangematin (INRA/SERD) met in 1998-99 under the chairmanship of Jean Alexis Grimaud, to plan 
and carry out the survey. 
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The survey consisted of several steps: 
1. Compilation of a list of enterprises engaged in biotechnology research, based on available 
sources; 
2. Validation of this list compiled by regional technology representatives, and addition of 
complementary data; 
3. Definition of a list of 450 target enterprises; 
4. Administration of the questionnaire; 
5. Processing of data and compilation of the directory. 
The survey gathered information on several dimensions: 
1. Identification of the firm; 
2. Ownership and creators; 
3. Targeted markets and technologies in use; 
4. Patents and certification; 
5. Financial information; 
6. Partnerships. 
 
 
List of variables 
Creation 1980-90 : Creation of the firm between 1980 and 1990 
A : Business model "Firms with high growth potential" 
sh vent. K : Venture capital firm a shareholder in the SME 
sh pers : Shareholder a natural person 
sh firm : Firm a shareholder of the SME 
Agri/envt : Targeted sector of the firm is agriculture, agro-food or environment 
After 90 : Creation of the firm after 1990 
Before 80 : Creation of the firm before 1980 
B : Business model : Firms which develop in niches 
Patent : hold patents 
C : business model : Firms attached to a group 
TO 1,5 and 15 Meuros : Turnover between 1.5 and 15 ME per year 
TO less than 1,5 Meuros : Turnover less than 1.5 ME per year 
TO up to 15 Meuros : Turnover up to 15 ME 
CNRS : Partnership with an academic organisation  
co-op labs : Academic partnerships 
final cons. : Firm supplies goods and services to the final consumer 
cosm ou veto : The targeted sector of the firm is veterinary products or cosmetic products 
Number of employees between 10 and 50 : Number of employees between 10 and 50 
Number of employees less than 10 : Number of employees less than 10 
Number of employees up to 50: Number of employees up to 50 
INRA : Partnership with an academic organisation dedicated to agronomic and agro-food research 
INSERM : Partnership with an academic organisation dedicated to medical research 
Pharma : The targeted sector is human health and pharmaceutical products 
Product : The firm sells products rather than services 
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R : Business model Recently set up firms 
 Standard : The firm's products are mass-produced rather than customised 
All sectors : The firm has no targeted sector. It produces generic research tools used by all sectors 
UNI : Partnership with university 
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Table 1: Activities of Biotechnology SMEs 
       Speciality    Total 
      Product 
development 
Development 
aid or 
sequencing 
methods 
Diagnosis 
and 
manufacturin
g of 
biological 
material 
Equipment 
and material 
  
Sectors 
Customers 
agri N° 
empl. 
17 1 27 3 48 
    %  35.4% 2.1% 56.3% 6.3% 100.0% 
  agri/cosmet. N° 
empl. 
1  1  2 
    %  50,0%  50,0%  100,0% 
  agri/cosmet./ph
arma. 
N° 
empl. 
2 3 15 2 22 
    %  9.1% 13.6% 68.2% 9.1% 100.0% 
  Cosmet. N° 
empl. 
4 1 2  7 
    %  57.1% 14.3% 28.6%  100.0% 
  Pharma. N° 
empl. 
13 20 32 3 68 
    %  19.1% 29.4% 47.1% 4.4% 100.0% 
  All N° 
empl. 
 6 25 8 39 
    %   15.4% 64.1% 20.5% 100.0% 
Total   N° 
empl. 
37 31 102 16 186 
    %  19.9% 16.7% 54.8% 8.6% 100.0% 
 
Khi-deux Tests 
  Value ddl Asymptomatic signification (bilateral) 
Pearson's Khi-deux  45.838 15 .000 
Probability 53.148 15 .000 
N° of valid observations 186     
a  13 cells (54.2%) have a theoretical number of employees of less than 5. The minimum theoretical number of employees is 
.17. 
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Table 2 : Size and age of biotechnology firms 
    Age  Total 
   Old Med Recent  
Customer sector Agri N° of 
empl. 
9 10 29 48 
  % 19% 21% 60% 100% 
 Agri/cosmet N° of 
empl. 
% 
  2 
100% 
2 
100% 
 Agri/cosmet/pharma N° of 
empl. 
1 5 16 22 
  % 5% 23% 73% 100% 
 Cosmet N° of 
empl. 
1 1 5 7 
  % 14% 14% 71% 100% 
 Pharma N° of 
empl. 
6 13 49 68 
  % 9% 19% 72% 100% 
 All N° of 
empl. 
3 8 28 39 
  % 8% 21% 72% 100% 
Total  N° of 
empl. 
20 37 129 186 
  % 11% 20% 69% 100% 
Khi-deux : Value 6,131, ddl : 10, significance : 0,80 
 
Average size of firms in number of employees 
  AGE 
Customer sector Customer sector Old Med Recent Total 
 Agri 99 28 30 42
 Agri/cosmet 8 8
 Agri/cosmet/pharma 98 12 20 22
 Cosmet 110 36 4 39
 Pharma 150 64 29 53
 All 20 22 11 14
Total  108 37 23 37
 
Table 3 : Distribution of firms, according to the dimensions of G. and A. Eliasson 
 Firms which target the final consumer Firms which produce intermediary 
products or services 
Intermediary firm or integrated firm 12.4% 87.6% 
 
 Venture capital firms Only natural persons Other companies Shareholders other 
than those listed 
Total 
Firms whose 
shareholders consist of 
28.5% 32.8% 33.9% 4.8% 100.0% 
 
 No patent At least one patent Total 
Mode of management of industrial property 65.6% 34.4% 100.0% 
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 No 
partnerships 
At least one 
partnership 
Of which with 
public labs 
Of which with 
universities 
Of which with foreign 
labs 
Firm's capacity to form 
academic partnerships 
40.9% 59.1% 40.3% 31.7% 6.5% 
 
Table 7 : Nature of competition for the different key resources 
 Group A Group B Group C 
Market and cash flow 
generated by the 
turnover 
International 
competition within this 
group. Competition 
with other actors such 
as large firms or 
academic laboratories 
Local competition at 
first, which spreads as 
the market expands. 
 
These firms compete 
with certain firms in 
Group B. 
Financial resources and 
shareholders. 
Competition between 
firms in this group to 
persuade investors and 
set up a round table of 
venture capital. 
Competition may also 
continue when the firm 
is listed on the stock 
market. 
When investors are in 
the family there is no 
competition. However, 
when the firms apply 
for local funding and 
investment from local 
venture capital firms, 
there may be 
competition. 
Firms in this group are 
financed by sales of 
products and services. 
Shareholding 
companies also provide 
capital. 
Relations with the 
academic community. 
Competition between 
firms in this group to 
develop relations with 
academic teams and to 
sign exclusive licence 
agreements with them 
if the university team 
has patented a 
technology. 
Relations with the 
academic community 
are formed on a basis 
of trust and 
partnership. 
Technologies are rarely 
patented. Niches are 
narrow and the number 
of competitors small. 
Close relations with 
the group's research 
centre. 
Relations with large 
companies. 
Competition to sign 
cooperative 
agreements. 
Few relations with 
large companies, 
except as suppliers. 
Few relations with 
companies that are 
shareholders' rivals. 
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Table 4 : Matrix of correlations between the different indicators 
    sh pers sh vent. K sh firm final cons. Product Production 
standard 
Agri ou env Pharma Cosm/veto All sectors  Hold patent Creation 
before 1980 
Creation 
1980-90 
Creation 
after 90 
co-op La
publics 
Sh pers Corr 1,000               
  Sig. ,               
Sh vent. K Corr ,226** 1,000              
  Sig. ,002 ,              
Sh firm Corr -,46** -,089 1,000             
  Sig. ,000 ,229 ,             
final cons. Corr -,130 ,052 ,086 1,000            
  Sig. ,077 ,478 ,241 ,            
Product Corr ,025 ,099 ,086 ,269** 1,000           
  Sig. ,737 ,177 ,241 ,000 ,           
Production  Corr ,002 ,026 ,087 ,323** ,732** 1,000          
 Standard Sig. ,978 ,728 ,239 ,000 ,000 ,          
Agri/envt Corr -,147* -,200** ,098 ,145* -,064 -,004 1,000         
  Sig. ,045 ,006 ,181 ,048 ,386 ,952 ,         
Pharma Corr ,098 ,111 ,036 -,131 -,133 -,149* -,413** 1,000        
  Sig. ,184 ,133 ,628 ,075 ,070 ,043 ,000 ,        
Cosm ou 
veto 
Corr ,115 ,023 -,064 ,197** ,091 ,106 -,129 -,003 1,000       
  Sig. ,117 ,755 ,388 ,007 ,215 ,149 ,080 ,965 ,       
All sectors  Corr ,039 ,055 -,052 -,193** ,062 ,038 -,369** -,493** -,174* 1,000      
  Sig. ,598 ,454 ,481 ,008 ,403 ,603 ,000 ,000 ,018 ,      
Hold  Corr ,032 ,295** ,112 ,106 ,207** ,142 -,040 ,009 ,129 -,039 1,000     
Patent Sig. ,668 ,000 ,129 ,150 ,004 ,053 ,587 ,908 ,078 ,593 ,     
Creation  Corr -,174* -,027 ,065 ,186* ,138 ,155* ,082 -,089 -,002 -,051 ,041 1,000    
Before 80 Sig. ,018 ,716 ,381 ,011 ,060 ,035 ,268 ,226 ,973 ,490 ,580 ,    
Creation Corr -,037 -,046 ,079 -,064 ,015 ,068 -,015 ,008 ,010 ,008 -,021 -,173* 1,000   
1980-90 Sig. ,620 ,533 ,284 ,382 ,837 ,359 ,837 ,914 ,894 ,914 ,779 ,018 ,   
Creation Corr ,148* ,058 -,112 -,069 -,106 -,163* -,042 ,053 -,007 ,027 -,010 -,522** -,750** 1,000  
After 90 Sig. ,043 ,432 ,129 ,348 ,149 ,026 ,572 ,472 ,926 ,712 ,898 ,000 ,000 ,  
co-op avec  Corr ,115 ,161 -,155* -,086 ,122 ,045 -,075 -,036 -,009 ,079 ,096 ,041 -,134 ,088 1,000 
Labos 
publics 
Sig. ,118 ,028 ,035 ,241 ,099 ,544 ,307 ,628 ,908 ,285 ,195 ,575 ,069 ,232 , 
**  Significance of the correlation at the level 0.01 (bilatéral). 
* Significance of the correlation at the level 0.05 (bilatéral). 
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Table 5 : Characteristics of each business model 
   A B C R sh pers Sh vent. 
K 
sh firm final Product standard Agri envt Pharma cosm ou 
veto 
All 
sectors 
Hold 
patent 
co-op 
labs 
INRA CNRS INSERM UNI 
A Corr 1,000                    
  Sig. ,                    
B Corr -,349** 1,000                   
  Sig. ,000 ,                   
C Corr -,211** -,383** 1,000                  
  Sig. ,004 ,000 ,                  
R Corr -,262** -,475** -,288** 1,000                 
  Sig. ,000 ,000 ,000 ,                 
sh pers Corr ,142 ,162 -,499 ,145 1,000                
  Sig. ,053 ,027 ,000 ,048 ,                
sh Krisk Corr ,371** -,282** -,212** ,190** ,226** 1,000               
  Sig. ,000 ,000 ,004 ,009 ,002 ,               
sh soc Corr -,127 -,234** ,467** -,050 -,467** -,089 1,000              
  Sig. ,085 ,001 ,000 ,496 ,000 ,229 ,              
final cons. Corr -,032 ,137 ,070 -,188* -,130 ,052 ,086 1,000             
  Sig. ,669 ,062 ,343 ,010 ,077 ,478 ,241 ,             
Product Corr ,005 ,009 ,054 -,062 ,025 ,099 ,086 ,269** 1,000            
  Sig. ,946 ,903 ,465 ,401 ,737 ,177 ,241 ,000 ,            
Standard Corr ,006 ,068 ,098 -,167* ,002 ,026 ,087 ,323** ,732** 1,000           
  Sig. ,939 ,358 ,183 ,023 ,978 ,728 ,239 ,000 ,000            
Agri / envt Corr -,159* ,201** ,150* -,222** -,147* -,200** ,098 ,145* -,064 -,004 1,000          
  Sig. ,030 ,006 ,042 ,002 ,045 ,006 ,181 ,048 ,386 ,952 ,          
Pharma Corr ,136 -,231** -,103 ,233** ,098 ,111 ,036 -,131 -,133 -,149* -,413** 1,000         
  Sig. ,064 ,002 ,161 ,001 ,184 ,133 ,628 ,075 ,070 ,043 ,000 ,         
Cosm /  Corr ,045 ,169 -,072 -,161* ,115 ,023 -,064 ,197** ,091 ,106 -,129 -,003 1,000        
 Veto Sig. ,541 ,021 ,332 ,028 ,117 ,755 ,388 ,007 ,215 ,149 ,080 ,965 ,        
All sectors Corr ,025 -,057 -,011 ,052 ,039 ,055 -,052 -,193** ,062 ,038 -,369** -,493** -,174* 1,000       
  Sig. ,730 ,441 ,877 ,483 ,598 ,454 ,481 ,008 ,403 ,603 ,000 ,000 ,018 ,       
Patent  Corr ,267** -,134 ,086 -,151* ,032 ,295** ,112 ,106 ,207** ,142 -,040 ,009 ,129 -,039 1,000      
 Détenu Sig. ,000 ,068 ,245 ,040 ,668 ,000 ,129 ,150 ,004 ,053 ,587 ,908 ,078 ,593 ,      
co-op labs Corr ,067 ,009 -,076 ,001 ,115 ,161* -,155* -,086 ,122 ,045 -,075 -,036 -,009 ,079 ,096 1,000     
  Sig. ,363 ,899 ,306 ,994 ,118 ,028 ,035 ,241 ,099 ,544 ,307 ,628 ,908 ,285 ,195 ,     
INRA Corr -,139 -,014 ,075 ,065 -,014 -,023 -,032 ,077 ,037 ,024 ,124 -,181* -,089 ,050 -,009 ,343** 1,000    
  Sig. ,058 ,848 ,309 ,375 ,847 ,751 ,664 ,296 ,617 ,748 ,091 ,014 ,229 ,496 ,899 ,000 ,    
CNRS Corr ,071 -,041 -,074 ,051 ,005 ,186* ,027 -,085 ,025 -,025 -,206** ,105 -,060 ,115 ,210** ,379** ,095 1,000   
  Sig. ,334 ,582 ,318 ,491 ,950 ,011 ,717 ,250 ,732 ,739 ,005 ,153 ,418 ,118 ,004 ,000 ,196 ,   
INSERM Corr ,134 -,129 -,131 ,147* ,070 ,254** ,005 -,071 ,026 -,038 -,245** ,360** ,002 -,149* ,219** ,357** ,033 ,197** 1,000  
  Sig. ,068 ,080 ,075 ,046 ,342 ,000 ,951 ,333 ,727 ,607 ,001 ,000 ,980 ,043 ,003 ,000 ,652 ,007 ,  
UNI Corr ,109 ,028 -,033 -,093 ,092 ,030 -,144 -,045 ,024 -,048 ,025 -,028 ,037 ,018 -,007 ,567** ,014 ,148* -,038 1,000 
  Sig. ,137 ,709 ,659 ,207 ,211 ,680 ,051 ,538 ,745 ,513 ,737 ,700 ,615 ,809 ,921 ,000 ,847 ,043 ,605 , 
**  Significance of the correlation at the level 0.01 (bilatéral). 
* Significance of the correlation at the level 0.05 (bilatéral). 
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Table 6 : The development of each business model 
    A B C R 
CA nul Corr -,143* -,298** -,177 ,606** 
  Sig. ,052 ,000 ,015 ,000 
TO less than Corr ,062 ,237** -,060 -,261** 
1,5 Meuros Sig. ,397 ,001 ,414 ,000 
TO between Corr ,055 ,014 ,250** -,283** 
 1,5 and 15 Meuros Sig. ,455 ,851 ,001 ,000 
TO up to  Corr ,051 ,049 ,034 -,127 
 15 Meuros Sig. ,488 ,505 ,650 ,085 
Number of employees Corr -,072 -,048 -,267** ,350** 
Less than 10 Sig. ,331 ,513 ,000 ,000 
Number of employees Corr ,031 ,025 ,185** -,218** 
Between 10 and 50 Sig. ,674 ,733 ,011 ,003 
Number of employees  Corr ,061 ,036 ,144* -,218** 
Up to 50 Sig. ,411 ,627 ,051 ,003 
**  Significance of the correlation at the level 0.01 (bilatéral). 
* Significance of the correlation at the level 0.05 (bilatéral). 
 
 
 
 
